Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review of tandem RET mutations with in silico analysis

Head and Neck

Volumn 35, Issue 12, 2013, Pages

  Nakao, Kanako Tanase ^a   Usui, Takeshi ^a   Ikeda, Mayumi ^a   Mori, Yusuke ^a   Yamamoto, Tetsuro ^a   Kawashima, Sachiko Tsukamoto ^a   Nanba, Kazutaka ^a   Yuno, Akiko ^a,b   Tamanaha, Tamiko ^a   Tagami, Tetsuya ^a   Naruse, Mitsuhide ^a   Asato, Ryo ^a   Shimatsu, Akira ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b Kin ikyo Chuo Hospital   (Japan)

Author keywords

de novo; in silico; MEN2B; RET; tandem mutation

Indexed keywords

ADULT; ARTICLE; CASE REPORT; COMPUTER MODEL; ECHOGRAPHY; ENDOCRINE TUMOR; FAMILY HISTORY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NECK TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SEQUENCE ALIGNMENT; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

DE NOVO; IN SILICO; MEN2B; RET; TANDEM MUTATION;

ADULT; AMINO ACID SUBSTITUTION; CALCITONIN; COMPUTER SIMULATION; FEMALE; GENOTYPE; GERM-LINE MUTATION; HUMANS; LYMPHATIC METASTASIS; MOUTH MUCOSA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NECK DISSECTION; PEDIGREE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84887992657     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23241     Document Type: Article

References (25)

1. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460.
2. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-376.
3. Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ,. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol 2011; 7: 596-607.
4. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
5. Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999; 90: 1-5.
6. Menko FH, van der Luijt RB, de Valk IA, et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 2002; 87: 393-397.
7. Cranston AN, Carniti C, Oakhill K, et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 2006; 66: 10179-10187.
8. Kasprzak L, Nolet S, Gaboury L, et al. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 2001; 38: 784-787.
9. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Höppner W,. A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 2000; 108: 128-132.
10. Toledo RA, Wagner SM, Coutinho FL, et al. High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab 2010; 95: 1318-1327.
11. Dvorakova S, Vaclavikova E, Ryska A, et al. Double germline mutations in the RET proto-oncogene in MEN 2A and MEN 2B kindreds. Exp Clin Endocrinol Diabetes 2006; 114: 192-196.
12. Poturnajova M, Altanerova V, Kostalova L, Breza J, Altaner C,. Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome. J Mol Med (Berl) 2005; 83: 287-295.
13. Tessitore A, Sinisi AA, Pasquali D, et al. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 1999; 84: 3522-3527.
14. Cosci B, Vivaldi A, Romei C, et al. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 2011; 18: 603-612.
15. Tsuru T, Usui T, Tsuji J, et al. Somatic mutation of RET proto-oncogene in sporadic medullary thyroid carcinoma. The Endocrinologist 2008; 18: 55-59.
16. Sambrook J, Russell D, Cold Spring Harbor Laboratory. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory; 2001.
17. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV,. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 2006; 34: 1317-1325.
18. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43: 295-305.
19. Grantham R,. Amino acid difference formula to help explain protein evolution. Science 1974; 185: 862-864.
20. Raue F, Frank-Raue K,. Update multiple endocrine neoplasia type 2. Fam Cancer 2010; 9: 449-457.
21. Crockett DK, Piccolo SR, Ridge PG, et al. Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene. PLoS One 2011; 6: e18380.
22. Kasprzak L, Nolet S, Gaboury L, et al. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 2001; 38: 784-787.
23. Maschek W, Pichler R, Rieger R, Weinhäusel A, Berg J,. A new identified germline mutation of the RET proto-oncogene responsible for familial medullary thyroid carcinoma in co-existence with a hyperfunctioning autonomous nodule. Clin Endocrinol (Oxf) 2002; 56: 823.
24. Fink M, Weinhüsel A, Niederle B, Haas OA,. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Int J Cancer 1996; 69: 312-316.
25. Iwashita T, Murakami H, Kurokawa K, et al. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem Biophys Res Commun 2000; 268: 804-808. Technology